Loading...

Fogelman Alan

TitleProfessor
InstitutionUniversity of California Los Angeles
DepartmentMedicine
Address10833 Le Conte Ave.
37-120 CHS
Los Angeles CA 90095
Phone(310) 825-8811
vCardDownload vCard
    Other Positions
    TitleDirector


    Collapse Research 
    Collapse Research Activities and Funding
    GORDON RESEARCH CONFERENCE ON ATHEROSCLEROSIS 1989
    NIH/NHLBI R13HL042904Jun 18, 1989 - Jun 17, 1990
    Role: Principal Investigator
    Lipid and Lipoprotein Metabolism in Atherosclerosis
    NIH/NHLBI P01HL030568Jul 1, 1983 - Apr 30, 2020
    Role: Principal Investigator
    PATHOPHYSIOLOGY OF MYOCARDIAL DISEASE
    NIH/NHLBI T32HL007412Jul 1, 1978 - Jun 30, 1994
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Chattopadhyay A, Yang X, Mukherjee P, Sulaiman D, Fogelman HR, Grijalva V, Dubinett S, Wasler TC, Paul MK, Salehi-Rad R, Mack JJ, Iruela-Arispe ML, Navab M, Fogelman A, Reddy ST. Treating the Intestine with Oral ApoA-I Mimetic Tg6F Reduces Tumor Burden in Mouse Models of Metastatic Lung Cancer. Sci Rep. 2018 Jun 13; 8(1):9032. PMID: 29899427.
      View in: PubMed
    2. Devarajan A, Su F, Grijalva V, Yalamanchi M, Yalamanchi A, Gao F, Trost H, Nwokedi J, Farias-Eisner G, Farias-Eisner R, Fogelman A, Reddy ST. Paraoxonase 2 overexpression inhibits tumor development in a mouse model of ovarian cancer. Cell Death Dis. 2018 Mar 12; 9(3):392. PMID: 29531225.
      View in: PubMed
    3. Wang B, Rong X, Palladino END, Wang J, Fogelman A, Martín MG, Alrefai WA, Ford DA, Tontonoz P. Phospholipid Remodeling and Cholesterol Availability Regulate Intestinal Stemness and Tumorigenesis. Cell Stem Cell. 2018 Feb 01; 22(2):206-220.e4. PMID: 29395055.
      View in: PubMed
    4. Fogelman A, Reddy ST. Making sense of a seemingly odd connection. Eur Heart J. 2017 Dec 21; 38(48):3588-3589. PMID: 29020393.
      View in: PubMed
    5. Mack JJ, Mosqueiro TS, Archer BJ, Jones WM, Sunshine H, Faas GC, Briot A, Aragón RL, Su T, Romay MC, McDonald AI, Kuo CH, Lizama CO, Lane TF, Zovein AC, Fang Y, Tarling EJ, de Aguiar Vallim TQ, Navab M, Fogelman A, Bouchard LS, Iruela-Arispe ML. NOTCH1 is a mechanosensor in adult arteries. Nat Commun. 2017 Nov 20; 8(1):1620. PMID: 29158473.
      View in: PubMed
    6. Yao J, Guihard PJ, Wu X, Blazquez-Medela AM, Spencer MJ, Jumabay M, Tontonoz P, Fogelman A, Boström KI, Yao Y. Vascular endothelium plays a key role in directing pulmonary epithelial cell differentiation. J Cell Biol. 2017 10 02; 216(10):3369-3385. PMID: 28838957.
      View in: PubMed
    7. Dunbar RL, Movva R, Bloedon LT, Duffy D, Norris RB, Navab M, Fogelman A, Rader DJ. Oral Apolipoprotein A-I Mimetic D-4F Lowers HDL-Inflammatory Index in High-Risk Patients: A First-in-Human Multiple-Dose, Randomized Controlled Trial. Clin Transl Sci. 2017 Nov; 10(6):455-469. PMID: 28795506.
      View in: PubMed
    8. Mukherjee P, Hough G, Chattopadhyay A, Navab M, Fogelman HR, Meriwether D, Williams K, Bensinger S, Moller T, Faull KF, Lusis AJ, Iruela-Arispe ML, Bostrom KI, Tontonoz P, Reddy ST, Fogelman A. Transgenic tomatoes expressing the 6F peptide and ezetimibe prevent diet-induced increases of IFN-ß and cholesterol 25-hydroxylase in jejunum. J Lipid Res. 2017 Aug; 58(8):1636-1647. PMID: 28592401.
      View in: PubMed
    9. Jumabay M, Zhumabai J, Mansurov N, Niklason KC, Guihard PJ, Cubberly MR, Fogelman A, Iruela-Arispe L, Yao Y, Saparov A, Boström KI. Combined effects of bone morphogenetic protein 10 and crossveinless-2 on cardiomyocyte differentiation in mouse adipocyte-derived stem cells. J Cell Physiol. 2018 Mar; 233(3):1812-1822. PMID: 28464239.
      View in: PubMed
    10. Li R, Yang J, Saffari A, Jacobs J, Baek KI, Hough G, Larauche MH, Ma J, Jen N, Moussaoui N, Zhou B, Kang H, Reddy S, Henning SM, Campen MJ, Pisegna J, Li Z, Fogelman A, Sioutas C, Navab M, Hsiai TK. Ambient Ultrafine Particle Ingestion Alters Gut Microbiota in Association with Increased Atherogenic Lipid Metabolites. Sci Rep. 2017 Feb 17; 7:42906. PMID: 28211537.
      View in: PubMed
    11. Cedó L, García-León A, Baila-Rueda L, Santos D, Grijalva V, Martínez-Cignoni MR, Carbó JM, Metso J, López-Vilaró L, Zorzano A, Valledor AF, Cenarro A, Jauhiainen M, Lerma E, Fogelman A, Reddy ST, Escolà-Gil JC, Blanco-Vaca F. ApoA-I mimetic administration, but not increased apoA-I-containing HDL, inhibits tumour growth in a mouse model of inherited breast cancer. Sci Rep. 2016 11 03; 6:36387. PMID: 27808249.
      View in: PubMed
    12. Meriwether D, Sulaiman D, Wagner A, Grijalva V, Kaji I, Williams KJ, Yu L, Fogelman S, Volpe C, Bensinger SJ, Anantharamaiah GM, Shechter I, Fogelman A, Reddy ST. Transintestinal transport of the anti-inflammatory drug 4F and the modulation of transintestinal cholesterol efflux. J Lipid Res. 2016 07; 57(7):1175-93. PMID: 27199144; PMCID: PMC4918848 [Available on 07/01/17].
    13. Mehta NU, Grijalva V, Hama S, Wagner A, Navab M, Fogelman A, Reddy ST. Apolipoprotein E-/- Mice Lacking Hemopexin Develop Increased Atherosclerosis via Mechanisms That Include Oxidative Stress and Altered Macrophage Function. Arterioscler Thromb Vasc Biol. 2016 Jun; 36(6):1152-63. PMID: 27079878; PMCID: PMC4882257 [Available on 06/01/17].
    14. Chattopadhyay A, Navab M, Hough G, Grijalva V, Mukherjee P, Fogelman HR, Hwang LH, Faull KF, Lusis AJ, Reddy ST, Fogelman A. Tg6F ameliorates the increase in oxidized phospholipids in the jejunum of mice fed unsaturated LysoPC or WD. J Lipid Res. 2016 05; 57(5):832-47. PMID: 26965826; PMCID: PMC4847630 [Available on 05/01/17].
    15. Wong MD, Guerrero L, Sallam T, Frank JS, Fogelman A, Demer LL. Outcomes of a Novel Training Program for Physician-Scientists: Integrating Graduate Degree Training With Specialty Fellowship. J Grad Med Educ. 2016 Feb; 8(1):85-90. PMID: 26913109; PMCID: PMC4763397 [Available on 02/01/17].
    16. Nguyen SD, Maaninka K, Lappalainen J, Nurmi K, Metso J, Öörni K, Navab M, Fogelman A, Jauhiainen M, Lee-Rueckert M, Kovanen PT. Carboxyl-Terminal Cleavage of Apolipoprotein A-I by Human Mast Cell Chymase Impairs Its Anti-Inflammatory Properties. Arterioscler Thromb Vasc Biol. 2016 Feb; 36(2):274-84. PMID: 26681753; PMCID: PMC4725095.
    17. Ross DJ, Hough G, Hama S, Aboulhosn J, Belperio JA, Saggar R, Van Lenten BJ, Ardehali A, Eghbali M, Reddy S, Fogelman A, Navab M. Proinflammatory high-density lipoprotein results from oxidized lipid mediators in the pathogenesis of both idiopathic and associated types of pulmonary arterial hypertension. Pulm Circ. 2015 Dec; 5(4):640-8. PMID: 26697171; PMCID: PMC4671738.
    18. Briot A, Civelek M, Seki A, Hoi K, Mack JJ, Lee SD, Kim J, Hong C, Yu J, Fishbein GA, Vakili L, Fogelman A, Fishbein MC, Lusis AJ, Tontonoz P, Navab M, Berliner JA, Iruela-Arispe ML. Endothelial NOTCH1 is suppressed by circulating lipids and antagonizes inflammation during atherosclerosis. J Exp Med. 2015 Nov 16; 212(12):2147-63. PMID: 26552708; PMCID: PMC4647265.
    19. Fogelman A. Further evidence that high-density lipoprotein is a chameleon-like lipoprotein. Eur Heart J. 2015 Nov 14; 36(43):3017-9. PMID: 26377399; PMCID: PMC4644254.
    20. Chattopadhyay A, Grijalva V, Hough G, Su F, Mukherjee P, Farias-Eisner R, Anantharamaiah GM, Faull KF, Hwang LH, Navab M, Fogelman A, Reddy ST. Efficacy of tomato concentrates in mouse models of dyslipidemia and cancer. Pharmacol Res Perspect. 2015 Aug; 3(4):e00154. PMID: 26171234; PMCID: PMC4492730.
    21. Nguyen SD, Javanainen M, Rissanen S, Zhao H, Huusko J, Kivelä AM, Ylä-Herttuala S, Navab M, Fogelman A, Vattulainen I, Kovanen PT, Öörni K. Apolipoprotein A-I mimetic peptide 4F blocks sphingomyelinase-induced LDL aggregation. J Lipid Res. 2015 Jun; 56(6):1206-21. PMID: 25861792; PMCID: PMC4442877.
    22. Navab M, Chattopadhyay A, Hough G, Meriwether D, Fogelman SI, Wagner AC, Grijalva V, Su F, Anantharamaiah GM, Hwang LH, Faull KF, Reddy ST, Fogelman A. Source and role of intestinally derived lysophosphatidic acid in dyslipidemia and atherosclerosis. J Lipid Res. 2015 Apr; 56(4):871-87. PMID: 25646365; PMCID: PMC4373744.
    23. Fogelman A. TMAO is both a biomarker and a renal toxin. Circ Res. 2015 Jan 30; 116(3):396-7. PMID: 25634968; PMCID: PMC4366001.
    24. Li R, Navab K, Hough G, Daher N, Zhang M, Mittelstein D, Lee K, Pakbin P, Saffari A, Bhetraratana M, Sulaiman D, Beebe T, Wu L, Jen N, Wine E, Tseng CH, Araujo JA, Fogelman A, Sioutas C, Navab M, Hsiai TK. Effect of exposure to atmospheric ultrafine particles on production of free fatty acids and lipid metabolites in the mouse small intestine. Environ Health Perspect. 2015 Jan; 123(1):34-41. PMID: 25170928; PMCID: PMC4286268.
    25. Reddy ST, Navab M, Anantharamaiah GM, Fogelman A. Apolipoprotein A-I mimetics. Curr Opin Lipidol. 2014 Aug; 25(4):304-8. PMID: 24977978; PMCID: PMC4213064.
    26. Sharma S, Umar S, Potus F, Iorga A, Wong G, Meriwether D, Breuils-Bonnet S, Mai D, Navab K, Ross D, Navab M, Provencher S, Fogelman A, Bonnet S, Reddy ST, Eghbali M. Apolipoprotein A-I mimetic peptide 4F rescues pulmonary hypertension by inducing microRNA-193-3p. Circulation. 2014 Aug 26; 130(9):776-85. PMID: 24963038; PMCID: PMC4194270.
    27. Fogelman A. Trying to harness the potential of HDL: wishful thinking or sound strategy? Eur Heart J. 2014 Dec 07; 35(46):3248-9. PMID: 24818600.
      View in: PubMed
    28. Lüscher TF, Landmesser U, von Eckardstein A, Fogelman A. High-density lipoprotein: vascular protective effects, dysfunction, and potential as therapeutic target. Circ Res. 2014 Jan 03; 114(1):171-82. PMID: 24385510.
      View in: PubMed
    29. Reddy ST, Navab M, Anantharamaiah GM, Fogelman A. Searching for a successful HDL-based treatment strategy. Biochim Biophys Acta. 2014 Jan; 1841(1):162-7. PMID: 24466591.
      View in: PubMed
    30. Fogelman A, Reddy ST, Navab M. Protection against ischemia/reperfusion injury by high-density lipoprotein and its components. Circ Res. 2013 Dec 06; 113(12):1281-2. PMID: 24311615.
      View in: PubMed
    31. Reddy ST, Navab M, Anantharamaiah GM, Fogelman A. Searching for a Successful HDL-based Treatment Strategy. Biochim Biophys Acta. 2013 Oct 24. PMID: 24513814.
      View in: PubMed
    32. Navab M, Hough G, Buga GM, Su F, Wagner AC, Meriwether D, Chattopadhyay A, Gao F, Grijalva V, Danciger JS, Van Lenten BJ, Org E, Lusis AJ, Pan C, Anantharamaiah GM, Farias-Eisner R, Smyth SS, Reddy ST, Fogelman A. Transgenic 6F tomatoes act on the small intestine to prevent systemic inflammation and dyslipidemia caused by Western diet and intestinally derived lysophosphatidic acid. J Lipid Res. 2013 Dec; 54(12):3403-18. PMID: 24085744; PMCID: PMC3826687.
    33. Kim JB, Hama S, Hough G, Navab M, Fogelman A, Maclellan WR, Horwich TB, Fonarow GC. Heart failure is associated with impaired anti-inflammatory and antioxidant properties of high-density lipoproteins. Am J Cardiol. 2013 Dec 01; 112(11):1770-7. PMID: 24050409.
      View in: PubMed
    34. Li R, Navab M, Pakbin P, Ning Z, Navab K, Hough G, Morgan TE, Finch CE, Araujo JA, Fogelman A, Sioutas C, Hsiai T. Ambient ultrafine particles alter lipid metabolism and HDL anti-oxidant capacity in LDLR-null mice. J Lipid Res. 2013 Jun; 54(6):1608-15. PMID: 23564731; PMCID: PMC3646462.
    35. Yin F, Lawal A, Ricks J, Fox JR, Larson T, Navab M, Fogelman A, Rosenfeld ME, Araujo JA. Diesel exhaust induces systemic lipid peroxidation and development of dysfunctional pro-oxidant and pro-inflammatory high-density lipoprotein. Arterioscler Thromb Vasc Biol. 2013 Jun; 33(6):1153-61. PMID: 23559632.
      View in: PubMed
    36. Chattopadhyay A, Navab M, Hough G, Gao F, Meriwether D, Grijalva V, Springstead JR, Palgnachari MN, Namiri-Kalantari R, Su F, Van Lenten BJ, Wagner AC, Anantharamaiah GM, Farias-Eisner R, Farias-Eisener R, Reddy ST, Fogelman A. A novel approach to oral apoA-I mimetic therapy. J Lipid Res. 2013 Apr; 54(4):995-1010. PMID: 23378594; PMCID: PMC3606004.
    37. Navab M, Reddy ST, Van Lenten BJ, Buga GM, Hough G, Wagner AC, Fogelman A. High-density lipoprotein and 4F peptide reduce systemic inflammation by modulating intestinal oxidized lipid metabolism: novel hypotheses and review of literature. Arterioscler Thromb Vasc Biol. 2012 Nov; 32(11):2553-60. PMID: 23077141; PMCID: PMC3597084.
    38. Kelesidis T, Reddy ST, Huynh D, Meriwether D, Fogelman A, Navab M, Yang OO. Effects of lipid-probe interactions in biochemical fluorometric methods that assess HDL redox activity. Lipids Health Dis. 2012 Jul 06; 11:87. PMID: 22768920; PMCID: PMC3409024.
    39. Gao F, Chattopadhyay A, Navab M, Grijalva V, Su F, Fogelman A, Reddy ST, Farias-Eisner R. Apolipoprotein A-I mimetic peptides inhibit expression and activity of hypoxia-inducible factor-1a in human ovarian cancer cell lines and a mouse ovarian cancer model. J Pharmacol Exp Ther. 2012 Aug; 342(2):255-62. PMID: 22537771; PMCID: PMC3400800.
    40. Hong C, Bradley MN, Rong X, Wang X, Wagner A, Grijalva V, Castellani LW, Salazar J, Realegeno S, Boyadjian R, Fogelman A, Van Lenten BJ, Reddy ST, Lusis AJ, Tangirala RK, Tontonoz P. LXRa is uniquely required for maximal reverse cholesterol transport and atheroprotection in ApoE-deficient mice. J Lipid Res. 2012 Jun; 53(6):1126-33. PMID: 22454476; PMCID: PMC3351819.
    41. Su F, Grijalva V, Navab K, Ganapathy E, Meriwether D, Imaizumi S, Navab M, Fogelman A, Reddy ST, Farias-Eisner R. HDL mimetics inhibit tumor development in both induced and spontaneous mouse models of colon cancer. Mol Cancer Ther. 2012 Jun; 11(6):1311-9. PMID: 22416044; PMCID: PMC3374063.
    42. Navab M, Reddy ST, Anantharamaiah GM, Hough G, Buga GM, Danciger J, Fogelman A. D-4F-mediated reduction in metabolites of arachidonic and linoleic acids in the small intestine is associated with decreased inflammation in low-density lipoprotein receptor-null mice. J Lipid Res. 2012 Mar; 53(3):437-45. PMID: 22167743; PMCID: PMC3276467.
    43. Kelesidis T, Currier JS, Huynh D, Meriwether D, Charles-Schoeman C, Reddy ST, Fogelman A, Navab M, Yang OO. A biochemical fluorometric method for assessing the oxidative properties of HDL. J Lipid Res. 2011 Dec; 52(12):2341-51. PMID: 21957198; PMCID: PMC3220300.
    44. Morgantini C, Natali A, Boldrini B, Imaizumi S, Navab M, Fogelman A, Ferrannini E, Reddy ST. Anti-inflammatory and antioxidant properties of HDLs are impaired in type 2 diabetes. Diabetes. 2011 Oct; 60(10):2617-23. PMID: 21852676; PMCID: PMC3178289.
    45. Meriwether D, Imaizumi S, Grijalva V, Hough G, Vakili L, Anantharamaiah GM, Farias-Eisner R, Navab M, Fogelman A, Reddy ST, Shechter I. Enhancement by LDL of transfer of L-4F and oxidized lipids to HDL in C57BL/6J mice and human plasma. J Lipid Res. 2011 Oct; 52(10):1795-809. PMID: 21804067; PMCID: PMC3173006.
    46. Besler C, Heinrich K, Rohrer L, Doerries C, Riwanto M, Shih DM, Chroni A, Yonekawa K, Stein S, Schaefer N, Mueller M, Akhmedov A, Daniil G, Manes C, Templin C, Wyss C, Maier W, Tanner FC, Matter CM, Corti R, Furlong C, Lusis AJ, von Eckardstein A, Fogelman A, Lüscher TF, Landmesser U. Mechanisms underlying adverse effects of HDL on eNOS-activating pathways in patients with coronary artery disease. J Clin Invest. 2011 Jul; 121(7):2693-708. PMID: 21701070; PMCID: PMC3223817.
    47. Vaziri ND, Navab K, Gollapudi P, Moradi H, Pahl MV, Barton CH, Fogelman A, Navab M. Salutary effects of hemodialysis on low-density lipoprotein proinflammatory and high-density lipoprotein anti-inflammatory properties in patient with end-stage renal disease. J Natl Med Assoc. 2011 Jun; 103(6):524-33. PMID: 21830637; PMCID: PMC3276406.
    48. Imaizumi S, Navab M, Morgantini C, Charles-Schoeman C, Su F, Gao F, Kwon M, Ganapathy E, Meriwether D, Farias-Eisner R, Fogelman A, Reddy ST. Dysfunctional high-density lipoprotein and the potential of apolipoprotein A-1 mimetic peptides to normalize the composition and function of lipoproteins. Circ J. 2011; 75(7):1533-8. PMID: 21628835; PMCID: PMC3625624.
    49. Ganapathy E, Su F, Meriwether D, Devarajan A, Grijalva V, Gao F, Chattopadhyay A, Anantharamaiah GM, Navab M, Fogelman A, Reddy ST, Farias-Eisner R. D-4F, an apoA-I mimetic peptide, inhibits proliferation and tumorigenicity of epithelial ovarian cancer cells by upregulating the antioxidant enzyme MnSOD. Int J Cancer. 2012 Mar 01; 130(5):1071-81. PMID: 21425255; PMCID: PMC3248802.
    50. Navab M, Reddy ST, Anantharamaiah GM, Imaizumi S, Hough G, Hama S, Fogelman A. Intestine may be a major site of action for the apoA-I mimetic peptide 4F whether administered subcutaneously or orally. J Lipid Res. 2011 Jun; 52(6):1200-10. PMID: 21444758; PMCID: PMC3090241.
    51. Kelesidis T, Yang OO, Currier JS, Navab K, Fogelman A, Navab M. HIV-1 infected patients with suppressed plasma viremia on treatment have pro-inflammatory HDL. Lipids Health Dis. 2011 Feb 23; 10:35. PMID: 21345230; PMCID: PMC3049748.
    52. Navab M, Reddy ST, Van Lenten BJ, Fogelman A. HDL and cardiovascular disease: atherogenic and atheroprotective mechanisms. Nat Rev Cardiol. 2011 Apr; 8(4):222-32. PMID: 21304474.
      View in: PubMed
    53. Gao F, Vasquez SX, Su F, Roberts S, Shah N, Grijalva V, Imaizumi S, Chattopadhyay A, Ganapathy E, Meriwether D, Johnston B, Anantharamaiah GM, Navab M, Fogelman A, Reddy ST, Farias-Eisner R. L-5F, an apolipoprotein A-I mimetic, inhibits tumor angiogenesis by suppressing VEGF/basic FGF signaling pathways. Integr Biol (Camb). 2011 Apr; 3(4):479-89. PMID: 21283904; PMCID: PMC3248743.
    54. Watson CE, Weissbach N, Kjems L, Ayalasomayajula S, Zhang Y, Chang I, Navab M, Hama S, Hough G, Reddy ST, Soffer D, Rader DJ, Fogelman A, Schecter A. Treatment of patients with cardiovascular disease with L-4F, an apo-A1 mimetic, did not improve select biomarkers of HDL function. J Lipid Res. 2011 Feb; 52(2):361-73. PMID: 21068008; PMCID: PMC3023557.
    55. Su F, Kozak KR, Imaizumi S, Gao F, Amneus MW, Grijalva V, Ng C, Wagner A, Hough G, Farias-Eisner G, Anantharamaiah GM, Van Lenten BJ, Navab M, Fogelman A, Reddy ST, Farias-Eisner R. Apolipoprotein A-I (apoA-I) and apoA-I mimetic peptides inhibit tumor development in a mouse model of ovarian cancer. Proc Natl Acad Sci U S A. 2010 Nov 16; 107(46):19997-20002. PMID: 21041624; PMCID: PMC2993420.
    56. Fogelman A. The complexity of high-density lipoproteins. Circulation. 2010 Nov 09; 122(19):1900-1. PMID: 20974995.
      View in: PubMed
    57. Morgantini C, Imaizumi S, Grijalva V, Navab M, Fogelman A, Reddy ST. Apolipoprotein A-I mimetic peptides prevent atherosclerosis development and reduce plaque inflammation in a murine model of diabetes. Diabetes. 2010 Dec; 59(12):3223-8. PMID: 20826564; PMCID: PMC2992786.
    58. Imaizumi S, Grijalva V, Navab M, Van Lenten BJ, Wagner AC, Anantharamiah GM, Fogelman A, Reddy ST. L-4F differentially alters plasma levels of oxidized fatty acids resulting in more anti-inflammatory HDL in mice. Drug Metab Lett. 2010 Aug; 4(3):139-48. PMID: 20642447; PMCID: PMC3037264.
    59. Imaizumi S, Grijalva V, Priceman S, Wu L, Su F, Farias-Eisner R, Hama S, Navab M, Fogelman A, Reddy ST. Mitogen-activated protein kinase phosphatase-1 deficiency decreases atherosclerosis in apolipoprotein E null mice by reducing monocyte chemoattractant protein-1 levels. Mol Genet Metab. 2010 Sep; 101(1):66-75. PMID: 20619710; PMCID: PMC3037189.
    60. Vaziri ND, Kim HJ, Moradi H, Farmand F, Navab K, Navab M, Hama S, Fogelman A, Quiroz Y, Rodriguez-Iturbe B. Amelioration of nephropathy with apoA-1 mimetic peptide in apoE-deficient mice. Nephrol Dial Transplant. 2010 Nov; 25(11):3525-34. PMID: 20488818; PMCID: PMC2980997.
    61. Woo JM, Lin Z, Navab M, Van Dyck C, Trejo-Lopez Y, Woo KM, Li H, Castellani LW, Wang X, Iikuni N, Rullo OJ, Wu H, La Cava A, Fogelman A, Lusis AJ, Tsao BP. Treatment with apolipoprotein A-1 mimetic peptide reduces lupus-like manifestations in a murine lupus model of accelerated atherosclerosis. Arthritis Res Ther. 2010; 12(3):R93. PMID: 20482780; PMCID: PMC2911877.
    62. Ruchala P, Navab M, Jung CL, Hama-Levy S, Micewicz ED, Luong H, Reyles JE, Sharma S, Waring AJ, Fogelman A, Lehrer RI. Oxpholipin 11D: an anti-inflammatory peptide that binds cholesterol and oxidized phospholipids. PLoS One. 2010 Apr 14; 5(4):e10181. PMID: 20418958.
      View in: PubMed
    63. Vaziri ND, Navab M, Fogelman A. HDL metabolism and activity in chronic kidney disease. Nat Rev Nephrol. 2010 May; 6(5):287-96. PMID: 20308998.
      View in: PubMed
    64. Buga GM, Navab M, Imaizumi S, Reddy ST, Yekta B, Hough G, Chanslor S, Anantharamaiah GM, Fogelman A. L-4F alters hyperlipidemic (but not healthy) mouse plasma to reduce platelet aggregation. Arterioscler Thromb Vasc Biol. 2010 Feb; 30(2):283-9. PMID: 19965777; PMCID: PMC2818809.
    65. Navab M, Anantharamaiah GM, Reddy ST, Van Lenten BJ, Fogelman A. HDL as a biomarker, potential therapeutic target, and therapy. Diabetes. 2009 Dec; 58(12):2711-7. PMID: 19940234; PMCID: PMC2780869.
    66. Charles-Schoeman C, Watanabe J, Lee YY, Furst DE, Amjadi S, Elashoff D, Park G, McMahon M, Paulus HE, Fogelman A, Reddy ST. Abnormal function of high-density lipoprotein is associated with poor disease control and an altered protein cargo in rheumatoid arthritis. Arthritis Rheum. 2009 Oct; 60(10):2870-9. PMID: 19790070; PMCID: PMC2828490.
    67. Navab M, Shechter I, Anantharamaiah GM, Reddy ST, Van Lenten BJ, Fogelman A. Structure and function of HDL mimetics. Arterioscler Thromb Vasc Biol. 2010 Feb; 30(2):164-8. PMID: 19608977; PMCID: PMC2860541.
    68. Vaziri ND, Moradi H, Pahl MV, Fogelman A, Navab M. In vitro stimulation of HDL anti-inflammatory activity and inhibition of LDL pro-inflammatory activity in the plasma of patients with end-stage renal disease by an apoA-1 mimetic peptide. Kidney Int. 2009 Aug; 76(4):437-44. PMID: 19471321; PMCID: PMC3280585.
    69. Watanabe J, Grijalva V, Hama S, Barbour K, Berger FG, Navab M, Fogelman A, Reddy ST. Hemoglobin and its scavenger protein haptoglobin associate with apoA-1-containing particles and influence the inflammatory properties and function of high density lipoprotein. J Biol Chem. 2009 Jul 03; 284(27):18292-301. PMID: 19433579; PMCID: PMC2709397.
    70. Navab M, Ruchala P, Waring AJ, Lehrer RI, Hama S, Hough G, Palgunachari MN, Anantharamaiah GM, Fogelman A. A novel method for oral delivery of apolipoprotein mimetic peptides synthesized from all L-amino acids. J Lipid Res. 2009 Aug; 50(8):1538-47. PMID: 19225094; PMCID: PMC2724044.
    71. Van Lenten BJ, Wagner AC, Anantharamaiah GM, Navab M, Reddy ST, Buga GM, Fogelman A. Apolipoprotein A-I mimetic peptides. Curr Atheroscler Rep. 2009 Jan; 11(1):52-7. PMID: 19080728; PMCID: PMC2856617.
    72. Van Lenten BJ, Navab M, Anantharamaiah GM, Buga GM, Reddy ST, Fogelman A. Multiple indications for anti-inflammatory apolipoprotein mimetic peptides. Curr Opin Investig Drugs. 2008 Nov; 9(11):1157-62. PMID: 18951294; PMCID: PMC2856620.
    73. Navab M, Reddy ST, Van Lenten BJ, Anantharamaiah GM, Fogelman A. The role of dysfunctional HDL in atherosclerosis. J Lipid Res. 2009 Apr; 50 Suppl:S145-9. PMID: 18955731; PMCID: PMC2674720.
    74. Cruz D, Watson AD, Miller CS, Montoya D, Ochoa MT, Sieling PA, Gutierrez MA, Navab M, Reddy ST, Witztum JL, Fogelman A, Rea TH, Eisenberg D, Berliner J, Modlin RL. Host-derived oxidized phospholipids and HDL regulate innate immunity in human leprosy. J Clin Invest. 2008 Aug; 118(8):2917-28. PMID: 18636118; PMCID: PMC2467381.
    75. Reddy ST, Devarajan A, Bourquard N, Shih D, Fogelman A. Is it just paraoxonase 1 or are other members of the paraoxonase gene family implicated in atherosclerosis? Curr Opin Lipidol. 2008 Aug; 19(4):405-8. PMID: 18607188.
      View in: PubMed
    76. Van Lenten BJ, Wagner AC, Jung CL, Ruchala P, Waring AJ, Lehrer RI, Watson AD, Hama S, Navab M, Anantharamaiah GM, Fogelman A. Anti-inflammatory apoA-I-mimetic peptides bind oxidized lipids with much higher affinity than human apoA-I. J Lipid Res. 2008 Nov; 49(11):2302-11. PMID: 18621920; PMCID: PMC2563211.
    77. Charles-Schoeman C, Banquerigo ML, Hama S, Navab M, Park GS, Van Lenten BJ, Wagner AC, Fogelman A, Brahn E. Treatment with an apolipoprotein A-1 mimetic peptide in combination with pravastatin inhibits collagen-induced arthritis. Clin Immunol. 2008 May; 127(2):234-44. PMID: 18337176.
      View in: PubMed
    78. Bloedon LT, Dunbar R, Duffy D, Pinell-Salles P, Norris R, DeGroot BJ, Movva R, Navab M, Fogelman A, Rader DJ. Safety, pharmacokinetics, and pharmacodynamics of oral apoA-I mimetic peptide D-4F in high-risk cardiovascular patients. J Lipid Res. 2008 Jun; 49(6):1344-52. PMID: 18323573; PMCID: PMC2386905.
    79. Navab M, Anantharamaiah GM, Reddy ST, Van Lenten BJ, Fogelman A. Apo A-1 mimetic peptides as atheroprotective agents in murine models. Curr Drug Targets. 2008 Mar; 9(3):204-9. PMID: 18336238.
      View in: PubMed
    80. Navab M, Anantharamaiah GM, Fogelman A. The effect of apolipoprotein mimetic peptides in inflammatory disorders other than atherosclerosis. Trends Cardiovasc Med. 2008 Feb; 18(2):61-6. PMID: 18308197; PMCID: PMC4365994.
    81. Buga GM, Frank JS, Mottino GA, Hakhamian A, Narasimha A, Watson AD, Yekta B, Navab M, Reddy ST, Anantharamaiah GM, Fogelman A. D-4F reduces EO6 immunoreactivity, SREBP-1c mRNA levels, and renal inflammation in LDL receptor-null mice fed a Western diet. J Lipid Res. 2008 Jan; 49(1):192-205. PMID: 17925450.
      View in: PubMed
    82. Van Lenten BJ, Wagner AC, Navab M, Anantharamaiah GM, Hama S, Reddy ST, Fogelman A. Lipoprotein inflammatory properties and serum amyloid A levels but not cholesterol levels predict lesion area in cholesterol-fed rabbits. J Lipid Res. 2007 Nov; 48(11):2344-53. PMID: 17693626.
      View in: PubMed
    83. Ansell BJ, Fonarow GC, Fogelman A. The paradox of dysfunctional high-density lipoprotein. Curr Opin Lipidol. 2007 Aug; 18(4):427-34. PMID: 17620860.
      View in: PubMed
    84. Anantharamaiah GM, Mishra VK, Garber DW, Datta G, Handattu SP, Palgunachari MN, Chaddha M, Navab M, Reddy ST, Segrest JP, Fogelman A. Structural requirements for antioxidative and anti-inflammatory properties of apolipoprotein A-I mimetic peptides. J Lipid Res. 2007 Sep; 48(9):1915-23. PMID: 17570869.
      View in: PubMed
    85. Watanabe J, Chou KJ, Liao JC, Miao Y, Meng HH, Ge H, Grijalva V, Hama S, Kozak K, Buga G, Whitelegge JP, Lee TD, Farias-Eisner R, Navab M, Fogelman A, Reddy ST. Differential association of hemoglobin with proinflammatory high density lipoproteins in atherogenic/hyperlipidemic mice. A novel biomarker of atherosclerosis. J Biol Chem. 2007 Aug 10; 282(32):23698-707. PMID: 17556366.
      View in: PubMed
    86. Charles-Schoeman C, Khanna D, Furst DE, McMahon M, Reddy ST, Fogelman A, Paulus HE, Park GS, Gong T, Ansell BJ. Effects of high-dose atorvastatin on antiinflammatory properties of high density lipoprotein in patients with rheumatoid arthritis: a pilot study. J Rheumatol. 2007 Jul; 34(7):1459-64. PMID: 17552046.
      View in: PubMed
    87. Navab M, Anantharamaiah GM, Reddy ST, Van Lenten BJ, Buga GM, Fogelman A. Peptide Mimetics of Apolipoproteins Improve HDL Function. J Clin Lipidol. 2007 May; 1(2):142-7. PMID: 18449337.
      View in: PubMed
    88. Ng CJ, Bourquard N, Hama SY, Shih D, Grijalva VR, Navab M, Fogelman A, Reddy ST. Adenovirus-mediated expression of human paraoxonase 3 protects against the progression of atherosclerosis in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol. 2007 Jun; 27(6):1368-74. PMID: 17446441.
      View in: PubMed
    89. Shih DM, Xia YR, Wang XP, Wang SS, Bourquard N, Fogelman A, Lusis AJ, Reddy ST. Decreased obesity and atherosclerosis in human paraoxonase 3 transgenic mice. Circ Res. 2007 Apr 27; 100(8):1200-7. PMID: 17379834; PMCID: PMC3740095.
    90. Narasimha A, Watanabe J, Lin JA, Hama S, Langenbach R, Navab M, Fogelman A, Reddy ST. A novel anti-atherogenic role for COX-2--potential mechanism for the cardiovascular side effects of COX-2 inhibitors. Prostaglandins Other Lipid Mediat. 2007 Aug; 84(1-2):24-33. PMID: 17643885; PMCID: PMC2701232.
    91. Ansell BJ, Fonarow GC, Navab M, Fogelman A. Modifying the anti-inflammatory effects of high-density lipoprotein. Curr Atheroscler Rep. 2007 Jan; 9(1):57-63. PMID: 17169248.
      View in: PubMed
    92. Navab M, Anantharamaiah GM, Reddy ST, Fogelman A. Apolipoprotein A-I mimetic peptides and their role in atherosclerosis prevention. Nat Clin Pract Cardiovasc Med. 2006 Oct; 3(10):540-7. PMID: 16990839.
      View in: PubMed
    93. Navab M, Anantharamaiah GM, Reddy ST, Van Lenten BJ, Ansell BJ, Fogelman A. Mechanisms of disease: proatherogenic HDL--an evolving field. Nat Clin Pract Endocrinol Metab. 2006 Sep; 2(9):504-11. PMID: 16957764.
      View in: PubMed
    94. Ansell BJ, Fonarow GC, Fogelman A. High-density lipoprotein: is it always atheroprotective? Curr Atheroscler Rep. 2006 Sep; 8(5):405-11. PMID: 16901411.
      View in: PubMed
    95. Ng CJ, Bourquard N, Grijalva V, Hama S, Shih DM, Navab M, Fogelman A, Lusis AJ, Young S, Reddy ST. Paraoxonase-2 deficiency aggravates atherosclerosis in mice despite lower apolipoprotein-B-containing lipoproteins: anti-atherogenic role for paraoxonase-2. J Biol Chem. 2006 Oct 06; 281(40):29491-500. PMID: 16891303.
      View in: PubMed
    96. Van Lenten BJ, Reddy ST, Navab M, Fogelman A. Understanding changes in high density lipoproteins during the acute phase response. Arterioscler Thromb Vasc Biol. 2006 Aug; 26(8):1687-8. PMID: 16857958.
      View in: PubMed
    97. McMahon M, Grossman J, FitzGerald J, Dahlin-Lee E, Wallace DJ, Thong BY, Badsha H, Kalunian K, Charles C, Navab M, Fogelman A, Hahn BH. Proinflammatory high-density lipoprotein as a biomarker for atherosclerosis in patients with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheum. 2006 Aug; 54(8):2541-9. PMID: 16868975.
      View in: PubMed
    98. Navab M, Anantharamaiah GM, Reddy ST, Van Lenten BJ, Datta G, Garber D, Fogelman A. Potential clinical utility of high-density lipoprotein-mimetic peptides. Curr Opin Lipidol. 2006 Aug; 17(4):440-4. PMID: 16832169.
      View in: PubMed
    99. Buga GM, Frank JS, Mottino GA, Hendizadeh M, Hakhamian A, Tillisch JH, Reddy ST, Navab M, Anantharamaiah GM, Ignarro LJ, Fogelman A. D-4F decreases brain arteriole inflammation and improves cognitive performance in LDL receptor-null mice on a Western diet. J Lipid Res. 2006 Oct; 47(10):2148-60. PMID: 16835442.
      View in: PubMed
    100. Anantharamaiah G, Navab M, Reddy ST, Garber DW, Datta G, Gupta H, White CR, Handattu SP, Palgunachari MN, Chaddha M, Mishra VK, Segrest JP, Fogelman A. Synthetic peptides: managing lipid disorders. Curr Opin Lipidol. 2006 Jun; 17(3):233-7. PMID: 16680027.
      View in: PubMed
    101. Reddy ST, Anantharamaiah GM, Navab M, Hama S, Hough G, Grijalva V, Garber DW, Datta G, Fogelman A. Oral amphipathic peptides as therapeutic agents. Expert Opin Investig Drugs. 2006 Jan; 15(1):13-21. PMID: 16370930.
      View in: PubMed
    102. Navab M, Anantharamaiah GM, Fogelman A. An apolipoprotein A-I mimetic works best in the presence of apolipoprotein A-I. Circ Res. 2005 Nov 25; 97(11):1085-6. PMID: 16306451.
      View in: PubMed
    103. Ansell BJ, Watson KE, Fogelman A, Navab M, Fonarow GC. High-density lipoprotein function recent advances. J Am Coll Cardiol. 2005 Nov 15; 46(10):1792-8. PMID: 16286161.
      View in: PubMed
    104. Navab M, Anantharamaiah GM, Reddy ST, Hama S, Hough G, Frank JS, Grijalva VR, Ganesh VK, Mishra VK, Palgunachari MN, Fogelman A. Oral small peptides render HDL antiinflammatory in mice and monkeys and reduce atherosclerosis in ApoE null mice. Circ Res. 2005 Sep 16; 97(6):524-32. PMID: 16100046.
      View in: PubMed
    105. Fogelman A. When pouring water on the fire makes it burn brighter. Cell Metab. 2005 Jul; 2(1):6-8. PMID: 16054094.
      View in: PubMed
    106. Navab M, Anantharamaiah GM, Reddy ST, Van Lenten BJ, Wagner AC, Hama S, Hough G, Bachini E, Garber DW, Mishra VK, Palgunachari MN, Fogelman A. An oral apoJ peptide renders HDL antiinflammatory in mice and monkeys and dramatically reduces atherosclerosis in apolipoprotein E-null mice. Arterioscler Thromb Vasc Biol. 2005 Sep; 25(9):1932-7. PMID: 15961700.
      View in: PubMed
    107. Navab M, Anantharamaiah GM, Fogelman A. The role of high-density lipoprotein in inflammation. Trends Cardiovasc Med. 2005 May; 15(4):158-61. PMID: 16099381.
      View in: PubMed
    108. Navab M, Anantharamaiah GM, Hama S, Hough G, Reddy ST, Frank JS, Garber DW, Handattu S, Fogelman A. D-4F and statins synergize to render HDL antiinflammatory in mice and monkeys and cause lesion regression in old apolipoprotein E-null mice. Arterioscler Thromb Vasc Biol. 2005 Jul; 25(7):1426-32. PMID: 15845909.
      View in: PubMed
    109. Navab M, Anantharamaiah GM, Reddy ST, Hama S, Hough G, Grijalva VR, Yu N, Ansell BJ, Datta G, Garber DW, Fogelman A. Apolipoprotein A-I mimetic peptides. Arterioscler Thromb Vasc Biol. 2005 Jul; 25(7):1325-31. PMID: 15831812.
      View in: PubMed
    110. Navab M, Ananthramaiah GM, Reddy ST, Van Lenten BJ, Ansell BJ, Hama S, Hough G, Bachini E, Grijalva VR, Wagner AC, Shaposhnik Z, Fogelman A. The double jeopardy of HDL. Ann Med. 2005; 37(3):173-8. PMID: 16019715.
      View in: PubMed
    111. Navab M, Anantharamaiah GM, Reddy ST, Van Lenten BJ, Datta G, Garber D, Fogelman A. Human apolipoprotein A-I and A-I mimetic peptides: potential for atherosclerosis reversal. Curr Opin Lipidol. 2004 Dec; 15(6):645-9. PMID: 15529023.
      View in: PubMed
    112. Ansell BJ, Navab M, Watson KE, Fonarow GC, Fogelman A. Anti-inflammatory properties of HDL. Rev Endocr Metab Disord. 2004 Dec; 5(4):351-8. PMID: 15486468.
      View in: PubMed
    113. Van Lenten BJ, Wagner AC, Navab M, Anantharamaiah GM, Hui EK, Nayak DP, Fogelman A. D-4F, an apolipoprotein A-I mimetic peptide, inhibits the inflammatory response induced by influenza A infection of human type II pneumocytes. Circulation. 2004 Nov 16; 110(20):3252-8. PMID: 15533864.
      View in: PubMed
    114. Barter PJ, Nicholls S, Rye KA, Anantharamaiah GM, Navab M, Fogelman A. Antiinflammatory properties of HDL. Circ Res. 2004 Oct 15; 95(8):764-72. PMID: 15486323.
      View in: PubMed
    115. Lusis AJ, Fogelman A, Fonarow GC. Genetic basis of atherosclerosis: part II: clinical implications. Circulation. 2004 Oct 05; 110(14):2066-71. PMID: 15466657.
      View in: PubMed
    116. Lusis AJ, Fogelman A, Fonarow GC. Genetic basis of atherosclerosis: part I: new genes and pathways. Circulation. 2004 Sep 28; 110(13):1868-73. PMID: 15451808.
      View in: PubMed
    117. Fogelman A. When good cholesterol goes bad. Nat Med. 2004 Sep; 10(9):902-3. PMID: 15340411.
      View in: PubMed
    118. Yan D, Navab M, Bruce C, Fogelman A, Jiang XC. PLTP deficiency improves the anti-inflammatory properties of HDL and reduces the ability of LDL to induce monocyte chemotactic activity. J Lipid Res. 2004 Oct; 45(10):1852-8. PMID: 15258196.
      View in: PubMed
    119. Reddy ST, Nguyen JT, Grijalva V, Hough G, Hama S, Navab M, Fogelman A. Potential role for mitogen-activated protein kinase phosphatase-1 in the development of atherosclerotic lesions in mouse models. Arterioscler Thromb Vasc Biol. 2004 Sep; 24(9):1676-81. PMID: 15242861.
      View in: PubMed
    120. Navab M, Anantharamaiah GM, Reddy ST, Hama S, Hough G, Grijalva VR, Wagner AC, Frank JS, Datta G, Garber D, Fogelman A. Oral D-4F causes formation of pre-beta high-density lipoprotein and improves high-density lipoprotein-mediated cholesterol efflux and reverse cholesterol transport from macrophages in apolipoprotein E-null mice. Circulation. 2004 Jun 29; 109(25):3215-20. PMID: 15197147.
      View in: PubMed
    121. Datta G, Epand RF, Epand RM, Chaddha M, Kirksey MA, Garber DW, Lund-Katz S, Phillips MC, Hama S, Navab M, Fogelman A, Palgunachari MN, Segrest JP, Anantharamaiah GM. Aromatic residue position on the nonpolar face of class a amphipathic helical peptides determines biological activity. J Biol Chem. 2004 Jun 18; 279(25):26509-17. PMID: 15075321.
      View in: PubMed
    122. Navab M, Ananthramaiah GM, Reddy ST, Van Lenten BJ, Ansell BJ, Fonarow GC, Vahabzadeh K, Hama S, Hough G, Kamranpour N, Berliner JA, Lusis AJ, Fogelman A. The oxidation hypothesis of atherogenesis: the role of oxidized phospholipids and HDL. J Lipid Res. 2004 Jun; 45(6):993-1007. PMID: 15060092.
      View in: PubMed
    123. Navab M, Reddy ST, Van Lenten BJ, Fogelman A. Apparent paradox of low-fat "healthy" diets increasing plasma levels of oxidized low-density lipoprotein and lipoprotein(a). Arterioscler Thromb Vasc Biol. 2004 Mar; 24(3):392-3. PMID: 15003971.
      View in: PubMed
    124. Ansell BJ, Navab M, Hama S, Kamranpour N, Fonarow G, Hough G, Rahmani S, Mottahedeh R, Dave R, Reddy ST, Fogelman A. Inflammatory/antiinflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment. Circulation. 2003 Dec 02; 108(22):2751-6. PMID: 14638544.
      View in: PubMed
    125. Castrillo A, Joseph SB, Vaidya SA, Haberland M, Fogelman A, Cheng G, Tontonoz P. Crosstalk between LXR and toll-like receptor signaling mediates bacterial and viral antagonism of cholesterol metabolism. Mol Cell. 2003 Oct; 12(4):805-16. PMID: 14580333.
      View in: PubMed
    126. Navab M, Hama S, Hough G, Fogelman A. Oral synthetic phospholipid (DMPC) raises high-density lipoprotein cholesterol levels, improves high-density lipoprotein function, and markedly reduces atherosclerosis in apolipoprotein E-null mice. Circulation. 2003 Oct 07; 108(14):1735-9. PMID: 14504179.
      View in: PubMed
    127. Navab M, Anantharamaiah GM, Reddy ST, Van Lenten BJ, Hough G, Wagner A, Nakamura K, Garber DW, Datta G, Segrest JP, Hama S, Fogelman A. Human apolipoprotein AI mimetic peptides for the treatment of atherosclerosis. Curr Opin Investig Drugs. 2003 Sep; 4(9):1100-4. PMID: 14582455.
      View in: PubMed
    128. Reddy ST, Hama S, Ng C, Grijalva V, Navab M, Fogelman A. ATP-binding cassette transporter 1 participates in LDL oxidation by artery wall cells. Arterioscler Thromb Vasc Biol. 2002 Nov 01; 22(11):1877-83. PMID: 12426219.
      View in: PubMed
    129. Van Lenten BJ, Wagner AC, Anantharamaiah GM, Garber DW, Fishbein MC, Adhikary L, Nayak DP, Hama S, Navab M, Fogelman A. Influenza infection promotes macrophage traffic into arteries of mice that is prevented by D-4F, an apolipoprotein A-I mimetic peptide. Circulation. 2002 Aug 27; 106(9):1127-32. PMID: 12196340.
      View in: PubMed
    130. Navab M, Hama SY, Reddy ST, Ng CJ, Van Lenten BJ, Laks H, Fogelman A, Ready ST. Oxidized lipids as mediators of coronary heart disease. Curr Opin Lipidol. 2002 Aug; 13(4):363-72. PMID: 12151851.
      View in: PubMed
    131. Reddy ST, Grijalva V, Ng C, Hassan K, Hama S, Mottahedeh R, Wadleigh DJ, Navab M, Fogelman A. Identification of genes induced by oxidized phospholipids in human aortic endothelial cells. Vascul Pharmacol. 2002 Apr; 38(4):211-8. PMID: 12449017.
      View in: PubMed
    132. Navab M, Anantharamaiah GM, Hama S, Garber DW, Chaddha M, Hough G, Lallone R, Fogelman A. Oral administration of an Apo A-I mimetic Peptide synthesized from D-amino acids dramatically reduces atherosclerosis in mice independent of plasma cholesterol. Circulation. 2002 Jan 22; 105(3):290-2. PMID: 11804981.
      View in: PubMed
    Alan's Networks
    Concepts
    Derived automatically from this person's publications.
    _
    Co-Authors
    People in Profiles who have published with this person.
    _
    Related Authors
    People who share related concepts with this person.
    _